Neuroprotective Effects of Bis(7)-tacrine in a Rat Model of Pressure-Induced Retinal Ischemia

Cell Biochemistry and Biophysics

Volumn 68, Issue 2, 2014, Pages 275-282

  Li, Jing bo ^a   Lu, Zhi gang ^b   Xu, Li ^a   Wang, Qi ^a   Zhang, Zu hai ^a   Fang, Jia hua ^a  

^a YANGTZE UNIVERSITY   (China)

^b First People's Hospital of Jingmen   (China)

Author keywords

Apoptosis; Bis(7) tacrine; Glaucoma; Ischemia reperfusion; Rat; Retina

Indexed keywords

1,7 N HEPTYLENE BIS 9,9' AMINO 1,2,3,4 TETRAHYDROACRIDINE; 1,7-N-HEPTYLENE-BIS-9,9'-AMINO-1,2,3,4-TETRAHYDROACRIDINE; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; PROTEIN P53; TACRINE;

ANIMAL; ARTICLE; DISEASE MODEL; DRUG EFFECT; ELECTRORETINOGRAPHY; ISCHEMIA; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSURE; RAT; RETINA DISEASE; RETINA GANGLION CELL; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; ISCHEMIA; MALE; NEUROPROTECTIVE AGENTS; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; RETINAL DISEASES; RETINAL GANGLION CELLS; TACRINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893910119     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9707-4     Document Type: Article

References (39)

1. Quigley, H. A., & Broman, A. T. (2006). The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology, 90, 262-267.
2. Fang, J. H., Jiang, F. G., Li, J. B., & Zhu, Y. H. (2012). Rationale for the use of multifunctional drugs as neuroprotective agents for glaucoma. Neural Regeneration Research, 7, 313-318.
3. Chidlow, G., Wood, J. P., & Casson, R. J. (2007). Pharmacological neuroprotection for glaucoma. Drugs, 67, 725-759.
4. Lafuente, M. P., Villegas-Perez, M. P., Mayor, S., Aguilera, M. E., Miralles de Imperial, J., & Vidal-Sanz, M. (2002). Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study. Experimental Eye Research, 74, 181-189.
5. Valenti, D. A. (2011). Alzheimer's disease and glaucoma: imaging the biomarkers of neurodegenerative disease. International Journal of Alzheimer's Disease, 2010, 793931.
6. Wostyn, P., Audenaert, K., & De Deyn, P. P. (2009). Alzheimer's disease and glaucoma: is there a causal relationship? British Journal of Ophthalmology, 93, 1557-1559.
7. Bayer, A. U., Keller, O. N., Ferrari, F., & Maag, K. P. (2002). Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. American Journal of Ophthalmology, 133, 135-137.
8. van der Schyf, C. J., & Youdim, M. B. (2009). Multifunctional drugs as neurotherapeutics. Neurotherapeutics, 6, 1-3.
9. Geldenhuys, W. J., Youdim, M. B., Carroll, R. T., & van der Schyf, C. J. (2011). The emergence of designed multiple ligands for neurodegenerative disorders. Progress in Neurobiology, 94, 347-359.
10. Zhao, Y., Li, W., Chow, P. C., Lau, D. T., Lee, N. T., Pang, Y., et al. (2008). Bis(7)-tacrine, a promising anti-Alzheimer's dimer, affords dose- and time-dependent neuroprotection against transient focal cerebral ischemia. Neuroscience Letters, 439, 160-164.
11. Sakamoto, K., Ohki, K., Saito, M., Nakahara, T., & Ishii, K. (2010). Histological protection by donepezil against neurodegeneration induced by ischemia-reperfusion in the rat retina. Journal of Pharmacological Sciences, 112, 327-335.
12. Fang, J. H., Wang, X. H., Xu, Z. R., & Jiang, F. G. (2010). Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage. BMC Neuroscience, 11, 31.
13. Zhang, Z. H., Liu, Y. W., Jiang, F. G., Tian, X., Zhu, Y. H., LI, J. B., Wang, Q., and Fang, J. H. (2011) Bis(7)-tacrine protects retinal ganglion cells against excitotoxicity via NMDA receptor inhibition, International Journal of Ophthalmology4, 125-130.
14. +) channel blocker, against neurotoxicity induced by ischemia-reperfusion in rat retina. Experimental Eye Research, 88, 974-982.
15. Pokroy, R., Tendler, Y., Pollack, A., Zinder, O., & Weisinger, G. (2002). p53 Expression in the normal murine eye. Investigative Ophthalmology and Visual Science, 43, 1736-1741.
16. Osborne, N. N. (2009). Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmologica, 87, 450-454.
17. Amitai, G., Ashani, Y., Grunfeld, Y., Kalir, A., & Cohen, S. (1976). Synthesis and properties of 2-S-(N, N-dialkylamino)ethyl)thio-1, 3, 2-dioxaphosphorinane 2-oxide and of the corresponding quaternary derivatives as potential nontoxic antiglaucoma agents. Journal of Medicinal Chemistry, 19, 810-813.
18. Goldblum, D., Garweg, J. G., & Bohnke, M. (2000). Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits. Journal of Ocular Pharmacology and Therapeutics, 16, 29-35.
19. Estermann, S., Daepp, G. C., Cattapan-Ludewig, K., Berkhoff, M., Frueh, B. E., & Goldblum, D. (2006). Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients. Journal of Ocular Pharmacology and Therapeutics, 22, 62-67.
20. Almasieh, M., Zhou, Y., Kelly, M. E., Casanova, C., & Di Polo, A. (2010). Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors. Cell Death Dis, 1, e27.
21. Li, W., Mak, M., Jiang, H., Wang, Q., Pang, Y., Chen, K., et al. (2009). Novel anti-Alzheimer's dimer bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics, 6, 187-201.
22. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408, 982-985.
23. McKinnon, S. J., Lehman, D. M., Kerrigan-Baumrind, L. A., Merges, C. A., Pease, M. E., Kerrigan, D. F., et al. (2002). Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Investigative Ophthalmology and Visual Science, 43, 1077-1087.
24. Guo, L., Salt, T. E., Luong, V., Wood, N., Cheung, W., Maass, A., et al. (2007). Targeting amyloid-beta in glaucoma treatment. Proceedings of the National Academy of Sciences USA, 104, 13444-13449.
25. Shimazawa, M., Inokuchi, Y., Okuno, T., Nakajima, Y., Sakaguchi, G., Kato, A., et al. (2008). Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling. Journal of Neurochemistry, 107, 279-290.
26. Silverman, R. B. (2009). Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases. Accounts of Chemical Research, 42, 439-451.
27. Park, S. H., Kim, J. H., Kim, Y. H., & Park, C. K. (2007). Expression of neuronal nitric oxide synthase in the retina of a rat model of chronic glaucoma. Vision Research, 47, 2732-2740.
28. Toda, N., & Nakanishi-Toda, M. (2007). Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Progress in Retinal and Eye Research, 26, 205-238.
29. Li, W., Lee, N. T., Fu, H., Kan, K. K., Pang, Y., Li, M., et al. (2006). Neuroprotection via inhibition of nitric oxide synthase by bis(7)-tacrine. NeuroReport, 17, 471-474.
30. Speidel, D. (2010). Transcription-independent p53 apoptosis: an alternative route to death. Trends in Cell Biology, 20, 14-24.
31. Rosenbaum, D. M., Rosenbaum, P. S., Gupta, H., Singh, M., Aggarwal, A., Hall, D. H., et al. (1998). The role of the p53 protein in the selective vulnerability of the inner retina to transient ischemia. Investigative Ophthalmology and Visual Science, 39, 2132-2139.
32. Joo, C. K., Choi, J. S., Ko, H. W., Park, K. Y., Sohn, S., Chun, M. H., et al. (1999). Necrosis and apoptosis after retinal ischemia: involvement of NMDA-mediated excitotoxicity and p53. Investigative Ophthalmology and Visual Science, 40, 713-720.
33. Li, Y., Schlamp, C. L., Poulsen, G. L., Jackson, M. W., Griep, A. E., & Nickells, R. W. (2002). p53 regulates apoptotic retinal ganglion cell death induced by N-methyl-D-aspartate. Mol Vis, 8, 341-350.
34. Ye, W., Gong, X., Xie, J., Wu, J., Zhang, X., Ouyang, Q., et al. (2010). AChE deficiency or inhibition decreases apoptosis and p53 expression and protects renal function after ischemia/reperfusion. Apoptosis, 15, 474-487.
35. Gurevich, L., & Slaughter, M. M. (1993). Comparison of the waveforms of the ON bipolar neuron and the b-wave of the electroretinogram. Vision Research, 33, 2431-2435.
36. Ji, D., Li, G. Y., & Osborne, N. N. (2008). Nicotinamide attenuates retinal ischemia and light insults to neurones. Neurochemistry International, 52, 786-798.
37. Song, Y., Gong, Y. Y., Xie, Z. G., Li, C. H., Gu, Q., & Wu, X. W. (2008). Edaravone (MCI-186), a free radical scavenger, attenuates retinal ischemia/reperfusion injury in rats. Acta Pharmacologica Sinica, 29, 823-828.
38. Block, F., & Schwarz, M. (1998). The b-wave of the electroretinogram as an index of retinal ischemia. General Pharmacology, 30, 281-287.
39. Kapin, M. A., Doshi, R., Scatton, B., DeSantis, L. M., & Chandler, M. L. (1999). Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia. Investigative Ophthalmology and Visual Science, 40, 1177-1182.